Iluzanebart 

Iluzanebart is a human monoclonal IgG1 antibody and is the agonist antibody for human TREM2 (hTREM2). Iluzanebart improves the survival and function of microglia by activating the TREM2 signaling pathway to compensate for the loss of CSF1R function. Iluzanebart can be used for research of adult-onset leukoencephalopathy associated with CSF1R (colony stimulating factor 1 receptor) (CSF1R-ALSP)^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

Triggering receptor expressed on myeloid cells 2 (TREM2)^[1]

Iluzanebart (0.1 nM-1 μM, 45 min) activates the TREM2 signaling pathway, increases the phosphorylation of SYK and DAP12 in cells HEK293T, hMDM and iMGL (EC₅₀ for SYK phosphorylation in HEK293T, hMDM and iMGL is 0.27 nM, 4.77 nM and 0.63 nM, respectively)^[1].
Iluzanebart (10 µg/mL, 48-96 h) restores PLX5622 (HY-114153)-induced cellular confluence and ramified morphology of cells hMDM and iMGL, and increases the cell viability^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Iluzanebart (1-200 mg/kg, ip, single dose) increases microglia proliferation and CSF1R levels in human TREM2 expressing transgenic mice models^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

144920.00

2733621-19-5

Liquid

Colorless to light yellow

[Iluzanebart]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized TREM-2 Protein, Human can bind Iluzanebart. The EC₅₀ for this effect is 178.6 ng/mL.

• [1]. Larson KC, et al., Rescue of in vitro models of CSF1R-related adult-onset leukodystrophy by iluzanebart: mechanisms and therapeutic implications of TREM2 agonism. J Neuroinflammation. 2025 Jan 31;22(1):26.  [Content Brief]